摘要
多形性胶质母细胞瘤是中枢神经系统最常见的恶性肿瘤，而且在胶质瘤中恶性程度最高。替莫唑胺为治疗多形性胶质母细胞瘤的新型烷化剂类口服化疗药物，研究表明替莫唑胺的耐药机制与O6-甲基鸟嘌呤．DNA甲基转移酶（MGMT）的表达相关。了解多形性胶质母细胞瘤应用替莫唑胺治疗的耐药性与MGMT表达的相关性对临床治疗很有帮助。
Glioblastoma multiforme （GBM） is one of the most frequently occurring tumors in the central nervous system and the most malignant tumor among gliomas. Temozolomide is a newly alkylating oral drug on the treatment of glioblastoma multiforme. Some studies indicated that protein expression of 06-methylguanine-DNA-methyhransferase （MGMT） is the most important determinant of TMZ resistance. Here, the relationship of MGMT expression with TMZ resistance in glioblastoma muhiforme patients will be reviewed.
出处
《国际免疫学杂志》
CAS
2012年第6期453-456,共4页
International Journal of Immunology
关键词
多形性胶质母细胞瘤
替莫唑胺
MGMT
Glioblastoma muhiforme
Temozolomide
O^6-methylgu-anine-DNA-methyltransferase
